Summary & Overview
HCPCS Level II J1750: Injection, Iron Dextran, 50 mg
HCPCS Level II code J1750 denotes a 50 mg injection of iron dextran, a parenteral iron therapy used to treat iron-deficiency when oral therapy is inadequate or intolerable. Nationally, injectable iron products are significant for managing anemia associated with chronic disease, renal failure, and other conditions where rapid repletion of iron stores is required. Accurate coding of J1750 affects claims processing, clinical documentation, and program-level tracking of parenteral iron utilization.
This analysis covers major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for J1750, typical sites of service, and the coding specifics necessary for claims. The publication summarizes common billing considerations, modifier usage patterns (listed separately), and related service-line implications. It also outlines benchmarking and policy-relevant items readers should monitor, such as coverage policies, prior authorization practices, and reimbursement norms for parenteral iron therapies.
The content is organized to support billing staff, revenue cycle teams, and policy analysts seeking a succinct reference on J1750—what the code represents, where it is used, and payer coverage scope at a national level.
Billing Code Overview
HCPCS Level II code J1750 represents an injection of iron dextran, 50 mg. This code describes the administration of an iron dextran product in a single 50 mg unit dose.
-
Service type: Parenteral drug administration (intravenous or intramuscular injection)
-
Typical site of service: Hospital outpatient departments, physician offices, infusion centers, and other outpatient infusion settings where injectable iron therapies are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with iron-deficiency anemia who has failed or is intolerant of oral iron therapy. The patient presents to an outpatient infusion center or physician office for parenteral iron dextran administration. Pre-procedure evaluation includes review of hemoglobin, ferritin, transferrin saturation, allergy history, and informed consent. A test dose may be administered per institutional protocol. The medication J1750 is prepared by pharmacy or nursing staff and administered via deep intramuscular injection or intravenous infusion per product guidelines and facility policy. Vital signs are monitored before, during, and after the injection; emergency medications and equipment for managing hypersensitivity or anaphylaxis are immediately available. After administration, the patient is observed for delayed reactions and provided discharge instructions regarding signs of allergic reaction and follow-up laboratory testing to assess iron repletion.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service | Use when a distinct E/M visit is provided on the same day as J1750 for evaluation unrelated to the injection itself. |